

# Emily B Ehlerding

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6773617/publications.pdf>

Version: 2024-02-01

39  
papers

2,157  
citations

304743

22  
h-index

302126

39  
g-index

39  
all docs

39  
docs citations

39  
times ranked

3662  
citing authors

#	ARTICLE	IF	CITATIONS
1	86/90Y-Labeled Monoclonal Antibody Targeting Tissue Factor for Pancreatic Cancer Theranostics. <i>Molecular Pharmaceutics</i> , 2020, 17, 1697-1705.	4.6	19
2	Molecular imaging of $\beta^2$ -cells: diabetes and beyond. <i>Advanced Drug Delivery Reviews</i> , 2019, 139, 16-31.	13.7	42
3	Multimodality Imaging Agents with PET as the Fundamental Pillar. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 2570-2579.	13.8	62
4	Multimodale Kontrastmittel für die kombinierte Positronenemissionstomographie. <i>Angewandte Chemie</i> , 2019, 131, 2592-2602.	2.0	8
5	A Melanin-Based Natural Antioxidant Defense Nanosystem for Theranostic Application in Acute Kidney Injury. <i>Advanced Functional Materials</i> , 2019, 29, 1904833.	14.9	111
6	Aptamer-Conjugated Framework Nucleic Acids for the Repair of Cerebral Ischemia-Reperfusion Injury. <i>Nano Letters</i> , 2019, 19, 7334-7341.	9.1	51
7	Site-Specific Immuno-PET Tracer to Image PD-L1. <i>Molecular Pharmaceutics</i> , 2019, 16, 2028-2036.	4.6	41
8	Noninvasive Imaging and Quantification of Radiotherapy-Induced PD-L1 Upregulation with $^{89}\text{Zr}$ - $^{64}\text{Cu}$ -Atezolizumab. <i>Bioconjugate Chemistry</i> , 2019, 30, 1434-1441.	3.6	34
9	CD146-Targeted Multimodal Image-Guided Photoimmunotherapy of Melanoma. <i>Advanced Science</i> , 2019, 6, 1801237.	11.2	42
10	Predicting PD-1/PD-L1 status in bladder cancer with $^{18}\text{F}$ -FDG PET?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 791-793.	6.4	1
11	Antibody-Based Tracers for PET/SPECT Imaging of Chronic Inflammatory Diseases. <i>ChemBioChem</i> , 2019, 20, 422-436.	2.6	23
12	Antibody and fragment-based PET imaging of CTLA-4+ T-cells in humanized mouse models. <i>American Journal of Cancer Research</i> , 2019, 9, 53-63.	1.4	19
13	Dual-labeled pertuzumab for multimodality image-guided ovarian tumor resection. <i>American Journal of Cancer Research</i> , 2019, 9, 1454-1468.	1.4	11
14	ImmunoPET imaging of CD38 expression in hepatocellular carcinoma using Cu-labeled daratumumab. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 6007-6015.	0.0	8
15	One-step synthesis of an $^{18}\text{F}$ -labeled boron-derived methionine analog: a substitute for $^{11}\text{C}$ -methionine?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 582-584.	6.4	2
16	Dual-Targeted Molecular Imaging of Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 390-395.	5.0	37
17	Noninvasive PET Imaging of T cells. <i>Trends in Cancer</i> , 2018, 4, 359-373.	7.4	88
18	Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models. <i>Molecular Pharmaceutics</i> , 2018, 15, 1627-1634.	4.6	19

#	ARTICLE	IF	CITATIONS
19	PET and SPECT imaging of melanoma: the state of the art. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 132-150.	6.4	29
20	<sup>89</sup> Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 110-120.	6.4	100
21	Targeting angiogenesis for radioimmunotherapy with a <sup>177</sup> Lu-labeled antibody. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 123-131.	6.4	17
22	PET Imaging of Receptor Tyrosine Kinases in Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1625-1636.	4.1	35
23	Albumin Hitchhiking with an Evans Blue Analog for Cancer Theranostics. <i>Theranostics</i> , 2018, 8, 812-814.	10.0	20
24	Chelator-Free Radiolabeling of Nanographene: Breaking the Stereotype of Chelation. <i>Angewandte Chemie</i> , 2017, 129, 2935-2938.	2.0	9
25	Chelator-Free Radiolabeling of Nanographene: Breaking the Stereotype of Chelation. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 2889-2892.	13.8	65
26	CD38 as a PET Imaging Target in Lung Cancer. <i>Molecular Pharmaceutics</i> , 2017, 14, 2400-2406.	4.6	25
27	Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1296-1305.	6.4	31
28	ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer. <i>Molecular Pharmaceutics</i> , 2017, 14, 1782-1789.	4.6	84
29	Chelator-Free Labeling of Metal Oxide Nanostructures with Zirconium-89 for Positron Emission Tomography Imaging. <i>ACS Nano</i> , 2017, 11, 12193-12201.	14.6	34
30	Preclinical Pharmacokinetics and Biodistribution Studies of <sup>89</sup> Zr-Labeled Pembrolizumab. <i>Journal of Nuclear Medicine</i> , 2017, 58, 162-168.	5.0	152
31	CD146-targeted immunoPET and NIRF Imaging of Hepatocellular Carcinoma with a Dual-Labeled Monoclonal Antibody. <i>Theranostics</i> , 2016, 6, 1918-1933.	10.0	57
32	Harnessing the Power of Molecular Imaging for Precision Medicine. <i>Journal of Nuclear Medicine</i> , 2016, 57, 171-172.	5.0	9
33	Smaller Agents for Larger Therapeutic Indices: Nanoscale Brachytherapy with <sup>177</sup> Lu-Labeled Gold Nanoparticles. <i>Journal of Nuclear Medicine</i> , 2016, 57, 834-835.	5.0	8
34	NanoLuc: A Small Luciferase Is Brightening Up the Field of Bioluminescence. <i>Bioconjugate Chemistry</i> , 2016, 27, 1175-1187.	3.6	383
35	Imaging the Biodistribution and Performance of Transplanted Stem Cells with PET. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1331-1332.	5.0	5
36	Molecular Imaging of Immunotherapy Targets in Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1487-1492.	5.0	77

#	ARTICLE	IF	CITATIONS
37	Cancer theranostics with <sup>64</sup> Cu/ <sup>177</sup> Lu-loaded liposomes. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 938-940.	6.4	9
38	<i>In Vivo</i> Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine. ACS Nano, 2015, 9, 3926-3934.	14.6	155
39	Theranostic Nanoparticles. Journal of Nuclear Medicine, 2014, 55, 1919-1922.	5.0	235